International regulatory requirements for genotoxicity testing for pharmaceuticals used in human medicine, and their impurities and metabolites. (16th March 2017)

• Record Type: Journal Article
• Authors: Galloway, Sheila M.
• Other Names: Gibbons Catherine F. guestEditor.; LeBaron Matthew J. guestEditor.
• Is Part Of: Environmental and molecular mutagenesis. Volume 58:Number 5(2017)
• Page Start: 296
• Page End: 324
• Publication Date: 2017-03-16
• Subjects: drugs -- guidelines -- strategy -- risk; Mutagenesis -- Periodicals; Molecular genetics -- Periodicals; Mutagenèse -- Périodiques; Mutagenèse chimique -- Périodiques; Mutation -- Périodiques; Maladies de l'environnement -- Périodiques; Génétique moléculaire -- Périodiques; 576.542
• DOI: 10.1002/em.22077
• Languages: English
• ISSNs: 0893-6692

Abstract

Abstract : The process of developing international (ICH) guidelines is described, and the main guidelines reviewed are the ICH S2(R1) guideline that includes the genotoxicity test battery for human pharmaceuticals, and the ICH M7 guideline for assessing and limiting potentially mutagenic impurities and degradation products in drugs. Key aspects of the guidelines are reviewed in the context of drug development, for example the incorporation of genotoxicity assessment into non‐clinical toxicity studies, and ways to develop and assess weight of evidence. In both guidelines, the existence of "thresholds" or non‐linear dose responses for genotoxicity plays a part in the strategies. Differences in ICH S2(R1) protocol recommendations from OECD guidelines are highlighted and rationales explained. The use of genotoxicity data during clinical development and in assessment of carcinogenic potential is also described. There are no international guidelines on assessment of potentially genotoxic metabolites, but some approaches to safety assessment are discussed for these. Environ. Mol. Mutagen. 58:296–324, 2017. © 2017 Wiley Periodicals, Inc.